FOLLOWUS
Apoptotic effect of cisplatin and cordycepin on OC3 human oral cancer cells
- Chinese Journal of Integrative Medicine Vol. 20, Issue 8, Pages: 624-632(2014)
- Affiliations：
1. Department of Anesthesia, Chi-Mei Medical Center, Liouying, Tainan,Taiwan,China
2. Department of Nursing, Min-Hwei College of Health Care Management, Tainan,Taiwan,China
3. Division of Endocrinology and Metabolism, Kaohsiung Veteran General Hospital Tainan Branch, Tainan,Taiwan,China
4. Department of Anesthesiology, Chang Gung Memorial Hospital and Kaohsiung Medical Center, Chang Gung University, Kaohsiung,Taiwan,China
5. Institute of Hot Spring Industry, Chia Nan University of Pharmacy and Science, Tainan,Taiwan,China
6. Department of Food Science and Technology, College of Human Ecology, HungKuang University, Taichung,Taiwan,China
7. Department of Cell Biology and Anatomy, and College of Medicine, National Cheng Kung University, Tainan,Taiwan,China
- Author bio：
- Funds：Supported by National Science Council Grant (No.98-2320-B-006-016), Taiwan, China
DOI：10.1007/s11655-013-1453-3
CLC：Published：2014，
Published Online：1 April 2013，
Scan for full text
Chen, Yh., Hao, LJ., Hung, Cp. et al. Apoptotic effect of cisplatin and cordycepin on OC3 human oral cancer cells., Chin. J. Integr. Med. 20, 624–632 (2014). https://doi.org/10.1007/s11655-013-1453-3
Ying-hui Chen, Lyh-Jyh Hao, Chih-peng Hung, et al. Apoptotic effect of cisplatin and cordycepin on OC3 human oral cancer cells. [J]. Chinese Journal of Integrative Medicine 20(8):624-632(2014)
Chen, Yh., Hao, LJ., Hung, Cp. et al. Apoptotic effect of cisplatin and cordycepin on OC3 human oral cancer cells., Chin. J. Integr. Med. 20, 624–632 (2014). https://doi.org/10.1007/s11655-013-1453-3 DOI：
Ying-hui Chen, Lyh-Jyh Hao, Chih-peng Hung, et al. Apoptotic effect of cisplatin and cordycepin on OC3 human oral cancer cells. [J]. Chinese Journal of Integrative Medicine 20(8):624-632(2014) DOI： 10.1007/s11655-013-1453-3.
摘要
To evaluate apoptotic effects of cisplatin and cordycepin as single agent or in combination with cytotoxicity in oral cancer cells. The influences of cisplatin (2.5 μg/mL) and/or cordycepin treatment (10 or 100 μmol/L) to human OC3 oral cancer cell line were investigated by morphological observation for cell death appearance
methylthiazoletetrazolium (MTT) assay for cell viability
flow cytometry assay for cell apoptosis
and Western blotting for apoptotic protein expressions. Data demonstrated that co-administration of cisplatin (2.5 μg/mL) and cordycepin (10 or 100 μmol/L) resulted in the enhancement of OC3 cell apoptosis compared to cisplatin or cordycepin alone treatment (24 h)
respectively (P <0.05). In flow cytometry assay
percentage of cells arrested at subG1 phase with co-treatment of cordycepin and cisplatin (30%) was significantly higher than cisplatin (5%) or cordycepin (12%) alone group (P <0.05)
confirming a synergistically apoptotic effect of cordycepin and cisplatin. In cellular mechanism study
co-treatment of cordycepin and cisplatin induced more stress-activated protein kinase/Jun terminal kinase (JNK)
the expressions of caspase-7
and the cleavage of poly ADP-ribose polymerase (PARP) as compared to cisplatin or cordycepin alone treatment (P <0.05). Cisplatin and cordycepin possess synergistically apoptotic effect through the activation of JNK/caspase-7/PARP pathway in human OC3 oral cancer cell line.
Abstract
To evaluate apoptotic effects of cisplatin and cordycepin as single agent or in combination with cytotoxicity in oral cancer cells. The influences of cisplatin (2.5 μg/mL) and/or cordycepin treatment (10 or 100 μmol/L) to human OC3 oral cancer cell line were investigated by morphological observation for cell death appearance
methylthiazoletetrazolium (MTT) assay for cell viability
flow cytometry assay for cell apoptosis
and Western blotting for apoptotic protein expressions. Data demonstrated that co-administration of cisplatin (2.5 μg/mL) and cordycepin (10 or 100 μmol/L) resulted in the enhancement of OC3 cell apoptosis compared to cisplatin or cordycepin alone treatment (24 h)
respectively (P <0.05). In flow cytometry assay
percentage of cells arrested at subG1 phase with co-treatment of cordycepin and cisplatin (30%) was significantly higher than cisplatin (5%) or cordycepin (12%) alone group (P <0.05)
confirming a synergistically apoptotic effect of cordycepin and cisplatin. In cellular mechanism study
co-treatment of cordycepin and cisplatin induced more stress-activated protein kinase/Jun terminal kinase (JNK)
the expressions of caspase-7
and the cleavage of poly ADP-ribose polymerase (PARP) as compared to cisplatin or cordycepin alone treatment (P <0.05). Cisplatin and cordycepin possess synergistically apoptotic effect through the activation of JNK/caspase-7/PARP pathway in human OC3 oral cancer cell line.
关键词
cisplatincordycepinapoptosisOC3synergistic
Keywords
cisplatincordycepinapoptosisOC3synergistic
references
Lin SC, Liu CJ, Chiu CP, Chang SM, Lu SY, Chen YJ. Establishment of OC3 oral carcinoma cell line and identification of NF-kappa B activation responses to areca nut extract. J Oral Pathol Med 2004;33:79–86.
Jin YT, Tsai ST, Wong TY, Chen FF, Chen RM. Studies on promoting activity of Taiwan betel quid ingredients in hamster buccal pouch carcinogenesis. Eur J Cancer B Oral Oncol 1996;32B:343–346.
Jeng JH, Chang MC, Hahn LJ. Role of areca nut in betel quid-associated chemical carcinogenesis: current awareness and future perspectives. Oral Oncol 2001;37:477–492.
Ho PS, Ko YC, Yang YH, Shieh TY, Tsai CC. The incidence of oropharyngeal cancer in Taiwan: an endemic betel quid chewing area. J Oral Pathol Med 2002;31:213–219.
Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Eng J Med 2003;349:2091–2098.
Psyrri A, Kwong M, DiStasio S, Lekakis L, Kassar M, Sasaki C, et al. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up. J Clin Oncol 2004;22:3061–3069.
Galetta D, Giotta F, Rosati G, Gebbia V, Manzione L, Di Bisceglie M, et al. Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell’Italia Meridionale (G.O.I.M.). Anticancer Res 2005;25:4445–4449.
Dollner R, Granzow C, Neudert M, Dietz A. Ex vivo chemosensitivity of head and neck carcinoma to cytostatic drug combinations. Anticancer Res 2006;26:1651–1655.
Boulikas T, Vougiouka M. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Oncol Rep 2004;11:559–595.
Juvekar AS, Adwankar MK, Tongaonkar HB. Effect of cisplatin-based chemotherapy on emergence of cisplatin resistance, and its correlation with intracellular glutathione levels and accumulation of p53 protein in human ovarian cancer. Cancer Biother Radiopharm 2000;15:295–300.
Blair BG, Larson CA, Safaei R, Howell SB. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of cisplatin and carboplatin. Clin Cancer Res 2009;15:4312–4321.
Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Mol Pharmacol 2009;75:1231–1239.
Mandic R, Rodgarkia-Dara CJ, Krohn V, Wiegand S, Grénman R, Werner JA. Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor. Anticancer Res 2009;29:1181–1187.
van den Broek GB, Wildeman M, Rasch CR, Armstrong N, Schuuring E, Begg AC, et al. Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation. Int J Cancer 2009;124:2643–2650.
Wang G, Reed E, Li QQ. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). Oncol Rep 2004;12:955–965.
Yan X, Fraser M, Qiu Q, Tsang BK. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatininduced apoptosis in a p53-dependent manner. Gynecol Oncol 2006;102:348–355.
Cunningham KG, Hutchinson SA, Manson W, Spring FS. Cordycepin, a metabolic product isolated from cultures of Cordyceps militaris. Nature 1950;166:949.
Wu WC, Hsiao JR, Lian YY, Lin CY, Huang BM. The apoptotic effect of cordycepin on human OEC-M1 oral cancer cell line. Cancer Chemother Pharmacol 2007;60:103–111.
Jen CY, Lin CY, Huang BM, Leu SF. Cordycepin induced MA-10 mouse leydig tumor cell apoptosis through caspase-9 pathway. Evid Based Complement Alternat Med 2011;2011:984537.
Nakamura K, Yoshikawa N, Yamaguchi Y, Kagota S, Shinozuka K, Kunitomo M. Antitumor effect of cordycepin (3-deoxyadenosine) on mouse melanoma and lung carcinoma cells involves adenosine A3 receptor stimulation. Anticancer Res 2006;26:43–47.
Tho madaki H, Tsiapalis CM, Scorilas A. Polyadenylate polymerase modulations in human epithelioid cervix and breast cancer cell lines, treated with etoposide or cordycepin, follow cell cycle rather than apoptosis induction. Biol Chem 2005;386:471–480.
Lallas GC, Courtis N, Havredaki M. K562 cell sensitization to 5-fluorouracil- or interferon-alpha-induced apoptosis via cordycepin (3-deoxyadenosine): fine control of cell apoptosis via poly(A) polymerase upregulation. Int J Biol Markers 2004;19:58–66.
Gupta S. Molecular steps of death receptor and mitochondrial pathways of apoptosis. Life Sci 2001;69:2957–2964.
Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S, et al. Role of poly (ADP-ribose) polymerase (PARP) cleavage in apoptosis — caspase 3 resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 1999;274:22932–22940.
Cryns V, Yuan J. Proteases to die for. Genes Dev 1998;12:1551–1570.
Yuan J, Horvitz HR. A first insight into the molecular mechanisms of apoptosis. Cell 2004;116:53–56.
Kim GY, Mercer SE, Ewton DZ, Yan Z, Jin K, Friedman E. The stress-activated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phosphorylation. J Biol Chem 2002;277:29792–29802.
Toh WH, Siddique MM, Boominathan L, Lin KW, Sabapathy K. C-Jun regulates the stability and activity of the p53 homologue, p73. J Biol Chem 2004;279:44713–44722.
Gupta PC, Warnakulasuriya S. Global epidemiology of areca nut usage. Addict Biol 2002;7:77–83.
Shneyvays V, Jacobson KA, Li AH, Nawrath H, Zinman T, Isaac A, et al. Induction of apoptosis in rat cardiocytes by A3 adenosine receptor activation and its suppression by isoproterenol. Exp Cell Res 2000;257:111–126.
Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986;89:271–277.
Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271–279.
Wang BJ, Won SJ, Yu ZR, Su CL. Free radical scavenging and apoptotic effects of cordycepin sinensis rationated by supercritical carbon dioxide. Food Chem Toxicol 2005;43:543–552.
Lowry OH, Rosenborough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol regent. J Biol Chem 1951;193:265–275.
Chen YJ, Huang YL, Huang BM. Cordyceps sinensis mycelium activates PKA and PKC signal pathways to stimulate steroidogenesis in MA-10 mouse Leydig tumor cells. Int J Biochem Cell Biol 2005;37:214–223.
Cory S. Cell death throes. Proc Natl Acad Sci USA 1998;95:12077–12079.
Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004;7:97–110.
Besançon R, Valsesia-Wittmann S, Puisieux A, de Fromentel CC, Maguer-Satta V. Cancer stem cells: the emerging challenge of drug targeting. Curr Med Chem 2009;16:394–416.
Bandoh N, Hayashi T, Takahara M, Kishibe K, Ogino T, Katayama A, et al. Loss of p21 expression is associated with p53 mutations and increased cell proliferation and p27 expression is associated with apoptosis in maxillary sinus squamous cell carcinoma. Acta Otolaryngol 2005;125:779–785.
Sreekanth CN, Bava SV, Sreekumar E, Anto RJ. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. Oncogene 2011;30:3139–3152.
Yoon CY, Park MJ, Lee JS, Lee SC, Oh JJ, Park H, et al. The histone deacetylase inhibitor trichostatin A synergistically resensitizes a cisplatin resistant human bladder cancer cell line. J Urol 2011;185:1102–1111.
Wong YY, Moon A, Duffin R, Barthet-Barateig A, Meijer HA, Clemens MJ, et al. Cordycepin inhibits protein synthesis and cell adhesion through effects on signal transduction. J Biol Chem 2010;285:2610–2621.
Smith KS, Folz BA, Adams EG, Bhuyan BK. Synergistic and additive combinations of several antitumor drugs and other agents with the potent alkylating agent adozelesin. Cancer Chemother Pharmacol 1995;35:471–482.
Choe MS, Zhang X, Shin HJ, Shin DM, Chen ZG. Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 2005;4:1448–1455.
Aissat N, Le Tourneau C, Ghoul A, Serova M, Bieche I, Lokiec F, et al. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 2008;62:305–313.
Hu R, Kim BR, Chen C, Hebbar V, Kong AN. The roles of JNK and apoptotic signaling pathways in PEITC-mediated responses in human HT-29 colon adenocarcinoma cells. Carcinogenesis 2003;24:1361–1367.
Khor TO, Cheung WK, Prawan A, Reddy BS, Kong AN. Chemoprevention of familial adenomatous polyposis in Apc(Min/+) mice by phenethyl isothiocyanate (PEITC). Mol Carcinog 2008;47:321–325.
Lee SJ, Moon GS, Jung KH, Kim WJ, Moon SK. c-Jun N-terminal kinase 1 is required for cordycepin-mediated induction of G2/M cell-cycle arrest via p21WAF1 expression in human colon cancer cells. Food Chem Toxicol 2010;48:277–283.
Lee SJ, Kim SK, Choi WS, Kim WJ, Moon SK. Cordycepin causes p21WAF1-mediated G2/M cell-cycle arrest by regulating c-Jun N-terminal kinase activation in human bladder cancer cells. Arch Biochem Biophys 2009;490:103–109.
Janus SC, Weurtz B, Ondrey FG. Inositol hexaphosphate and paclitaxel: symbiotic treatment of oral cavity squamous cell carcinoma. Laryngoscope 2007;117:1381–1388.
0
Views
826
Downloads
15
CSCD
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
- Tel：010-62886827, 62877592 Fax：010-62874291
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
